Study of S100B Protein Levels in Cord Blood to Detect Brain Oxygen Problems in Full-Term Babies With and Without Fetal Growth Restriction

What this Trial Is About

Researchers are studying the use of S100B protein levels as a biomarker to detect early brain damage in newborns affected by fetal growth restriction FGR. The study compares two groups of full-term pregnancies one group with late-onset FGR diagnosed before birth and a control group with normal fetal growth. The goal is to understand if measuring S100B in cord blood can help identify infants at risk for developmental problems related to brain hypoxia-ischemia. The study involves prenatal ultrasound exams within 48 hours before delivery to assess fetal blood flow in several arteries. After birth, cord blood samples are collected to measure S100B protein levels, pH, base excess, and lactate. Additionally, newborns undergo a transfontanelle ultrasound to check for abnormalities. Samples are processed and analyzed to compare the two groups and assess relationships between protein levels and other blood and ultrasound markers. Participants will provide cord blood and ultrasound data shortly before and after delivery. Researchers will analyze S100B concentrations and their correlation with blood gas values and fetal blood flow parameters. The main outcome is the S100B level in cord blood within three months of enrollment. This observational study helps understand the potential of S100B as a diagnostic marker for brain oxygen deprivation in babies with FGR.

Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction